medRxiv preprint doi: https://doi.org/10.1101/2024.01.30.24301996; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.



24 Hills Road, P 01223 855346 Cambridge W elifesciences.org CB2 1JP T @elife\_sciences

FOR PEER REVIEW - CONFIDENTIAL

#### eLife reviews are now Public Reviews

Beginning in December 2020, eLife is changing our editorial process to emphasize the production of **clear**, **transparent public reviews** of papers already published as **preprints** that will transform unrefereed author manuscripts into publicly accessible **refereed preprints**.

In doing so, our goal is not simply to take existing peer reviews and post them online. Rather we want to change how we construct and write peer reviews to make them useful to both authors and readers in a way that better reflects the work you as a reviewer put into reading and thinking about a paper.

eLife reviews now have three parts:

- An **evaluation summary** that is a concise summary of your assessment of the work's major strengths and weaknesses in general terms and its likely impact.
- A public review that details the strengths and weaknesses of the manuscript before you, and discusses whether the authors' claims and conclusions are justified by their data.
- A set of private **recommendations for the authors** that outline how you think the science and its presentation could be strengthened.

All three sections will be used as the basis for an eLife publishing decision, which will, as always, be made after a consultation among the reviewers and editor. The two public sections will then be published alongside the preprint, along with a response from the authors if they choose (in the case of papers we reject after review, the authors can choose to delay posting until their paper is published elsewhere).

If this is your first time going through this new process, we ask that you take some time to read our <u>Reviewer Guide</u>, which discusses how we see each section will be used, what it should contain, and what we hope it accomplishes. And we remind you that, with the shift of reviews from private correspondence to public discourse, it is more important than ever that reviews are written in a **clear and constructive manner** appropriate for a public audience and mindful of the impact language choices might have on the authors.

#### Information about the manuscript

## The CoLab-score rapidly and efficiently excludes COVID-19 at the emergency department without need for SARS-CoV-2 testing: a multicenter case-control study

Tracking no: 10-03-2021-RA-eLife-68276

**Impact statement:** The CoLab-score can rapidly and safely exclude a possible COVID-19-infection in patients presenting at the ER, based on ten routine laboratory tests and age.

Competing interests: No competing interests declared

#### Author contributions:

Arjen-Kars Boer: Conceptualization; Resources; Data curation; Formal analysis; Supervision; Validation; Investigation; Visualization; Methodology; Writing - review and editing Ruben Deneer: Conceptualization; Data curation; Software; Formal analysis; Validation; Visualization; Methodology; Writing - original draft; Writing - review and editing Maaike Maas: Conceptualization; Supervision; Writing - review and editing Heidi Ammerlaan: Conceptualization; Resources; Supervision; Writing - review and editing Roland van Balkom: Conceptualization; Supervision; Writing - review and editing Mathie Leers: Resources; Data curation; Validation; Writing - review and editing Romy Martens: Resources; Data curation; Validation; Writing - review and editing Madelon Buijs: Resources; Data curation; Validation; Writing - review and editing Jos Kerremans: Resources; Data curation; Validation; Writing - review and editing Jeroen van Suijlen: Resources; Data curation; Validation; Writing - review and editing Natal van Riel: Resources; Supervision; Methodology; Writing - review and editing Volkher Scharnhorst: Conceptualization; Resources; Supervision; Project administration; Writing - review and editing

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2024.01.30.24301996; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

#### Funding:

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

#### **Data Availability:**

Source data to generate figures and tables is provided. It is however, not possible to provide the development dataset used to fit the model since this contains patient data which is subject to EU GDPR regulation. Therefore the source data for Table 1 is split into categories and ordered to prevent patient re-identification. If an interested researcher would like to obtain access to the development dataset, an e-mail to the manager of the data (arjen-kars.boer@catharinaziekenhuis.nl) with a research proposal would have to be sent. This proposal will be reviewed by the hospital IRB.

N/A

#### Ethics:

Human Subjects: Yes Ethics Statement: The study was reviewed by the Medical research Ethics Committees United (MEC-U) under study number W20.071, which confirmed that the Medical Research Involving Human Subjects Act (In Dutch: WMO) does not apply to this study. The study was thereafter reviewed and approved by the internal hospital review board. Clinical Trial: No Animal Subjects: No

medRxiv preprint doi: https://doi.org/10.1101/2024.01.30.24301996; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license. The CoLab-score rapidly and efficiently excludes COVID-19 at the 1 emergency department without need for SARS-CoV-2 testing: a 2 multicenter case-control study 3 4 Arjen-Kars Boer<sup>1,2\*</sup>, Ruben Deneer<sup>1,2,3\*†</sup>, Maaike Maas<sup>4</sup>, Heidi S. M. Ammerlaan<sup>5</sup>, Roland H. H. van 5 Balkom<sup>6</sup>, Mathie P. G. Leers<sup>7</sup>, Remy J.H. Martens<sup>7</sup>, Madelon M. Buijs<sup>8</sup>, Jos J. Kerremans<sup>9</sup>, Muriël 6 7 Messchaert<sup>10</sup>, Jeroen D.E. van Suijlen<sup>10</sup>, Natal A.W. van Riel<sup>2,3</sup> and Volkher Scharnhorst<sup>1,2,3</sup> 8 9 \* Both authors contributed equally 10 <sup>†</sup> Corresponding author 11 12 1 Department of Laboratory Medicine, Catharina Hospital Eindhoven, Michelangelolaan 2, 13 5623 EJ, Eindhoven, the Netherlands 2 Expert Center Clinical Chemistry Eindhoven, Michelangelolaan 2, 5623 EJ, Eindhoven, 14 15 the Netherlands 3 Faculty of Biomedical Engineering, Technical University Eindhoven, Groene Loper 3, 16 17 5612 AE, Eindhoven, the Netherlands 4 Department of Emergency Medicine, Catharina Hospital Eindhoven, Michelangelolaan 2, 18 19 5623 EJ, Eindhoven, the Netherlands 5 Department of Internal Medicine, Catharina Hospital Eindhoven, Michelangelolaan 2, 20 21 5623 EJ, Eindhoven, the Netherlands 22 6 Department of Pulmonary Diseases, Catharina Hospital Eindhoven, Michelangelolaan 2, 23 5623 EJ, Eindhoven, the Netherlands 7 24 Department of Laboratory Medicine, Zuyderland Medical Center, Dr. H. van der 25 Hoffplein 1, 6162 BG, Sittard-Geleen, the Netherlands

1

| me | edRxiv preprint o  | toi: https://doi.org/10.1101/2024.01.30.24301996; this version posted January 31, 2024. The copyright holder for this preprint <b>to certified by peer review)</b> is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. |  |  |  |  |  |
|----|--------------------|---|--|--|--|--|--|
| 26 | 8                  | Atalmedial Diagnostic Centers, Jan Tooropstraat 138, 1061 AD Amsterdam, the   |  |  |  |  |  |
| 27 |                    | Netherlands   |  |  |  |  |  |
| 28 | 9                  | Department of Medical Microbiology & Infection Prevention, Alrijne Hospital, Simon  |  |  |  |  |  |
| 29 |                    | Smitweg 1, 2353 GA Leiderdorp, the Netherlands  |  |  |  |  |  |
| 30 | 10                 | Department of Clinical Chemistry, Gelre Hospital, Albert Schweitzerlaan 31, 7334 DZ   |  |  |  |  |  |
| 31 |                    | Apeldoorn, the Netherlands  |  |  |  |  |  |
| 32 |                    |   |  |  |  |  |  |
| 33 | Correspond         | ding author details   |  |  |  |  |  |
| 34 | Ruben Deneer       |   |  |  |  |  |  |
| 35 | Michelang          | elolaan 2   |  |  |  |  |  |
| 36 | 5623 EJ Eindhoven  |   |  |  |  |  |  |
| 37 | +31 (0)40 239 9111 |   |  |  |  |  |  |
|    |                    |   |  |  |  |  |  |

38 ruben.deneer@catharinaziekenhuis.nl

medRxiv preprint doi: https://doi.org/10.1101/2024.01.30.24301996; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

#### 39 Abstract

#### 40 Background

- 41 Rapid identification of emergency department (ED) patients with a possible COVID-19 infection is
- 42 needed. PCR-testing all ED patients is neither feasible nor effective in most centers, therefore a rapid,
- 43 objective, low-cost screening tool to triage ED patients is necessary.

#### 44 Methods

- 45 Results from all routine lab tests from ED patients at the Catharina Hospital were collected from July
- 46 2019 to July 2020 and used in a statistical model to obtain the CoLab-score. The score was validated
- 47 temporally and externally in three independent centers.
- 48 Results
- 49 The CoLab-score consists of 10 routine lab results and can be used to safely rule-out a COVID-19
- 50 infection in more than one third of ED presentations with a negative predictive value of 0.997 (95%
- 51 CI: 0.994 0.999).

#### 52 Conclusions

- 53 The CoLab-score is a valuable tool to rule out COVID-19, guide PCR testing and is available to any
- 54 center with access to routine laboratory tests.

medRxiv preprint doi: https://doi.org/10.1101/2024.01.30.24301996; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

#### 55 Introduction

56 A global pandemic caused by a novel virus like severe acute respiratory syndrome coronavirus 2 57 (SARS-CoV-2) disrupts society, the health system and hospitals in particular. Initially, little was 58 known about the virus, its transmission, the diagnostic possibilities and treatment options. Combined 59 with limited awareness in the community, the virus spread swiftly, resulting in exponential growth of 60 infected patients. Interventions like social distancing and face masks subsequently resulted in a decline 61 in prevalence of the virus. But after a low prevalence at the start of the summer, there was a revival of 62 the virus in the fall, resulting in a second wave ("Coronavirus Disease (COVID-19) Situation 63 Reports," n.d.). Faced with novel mutations in SARS-CoV-2, in many countries a third wave is very 64 likely to occur. In all phases of the outbreak, emergency departments (EDs) faced different diagnostic 65 challenges. Often, the capacity of the SARS-CoV-2 RNA PCR testing facility was limited and patient care was delayed due to the long turnaround time of centralized PCR facilities. Shortly after the first 66 67 wave, rapid SARS-CoV-2 tests became available, potentially reducing the diagnostic phase to less 68 than 1 hour.

69 Prediction models that reliably identify ED patients eligible for PCR testing, or safely rule-out patients without coronavirus disease 2019 (COVID-19), are desirable. Moreover, if only routine laboratory 70 71 results are required as input, a model could potentially reduce diagnostic costs and accelerate triaging 72 of patients. In the era of algorithms and artificial intelligence, it is very appealing to develop predictive 73 or diagnostic tools based on information readily available. In fact, models have been developed to 74 identify SARS-CoV-2-positive patients (Brinati et al., 2020; Fink et al., 2020; Giamello et al., 2020; 75 Joshi et al., 2020; Kurstjens et al., 2020; Plante et al., 2020; Qin et al., 2020; Tordjman et al., 2020), to 76 describe the severity of COVID-19 symptoms or to predict deterioration or ultimately admission at the 77 intensive care unit (Linssen et al., 2020; Wang et al., 2020; Zeng et al., 2021; Zhou et al., 2020). For 78 an extensive overview and critical appraisal of models developed for COVID-19 we refer to the living 79 systematic review by Wynants et. al (Wynants et al., 2020). However, only few models found their 80 way into routine care at the ED (Albahri et al., 2020; Hooli and King, 2020). Early models were based 81 on relatively small sample sizes, were hampered by selection bias or required features that could not

medRxiv preprint doi: https://doi.org/10.1101/2024.01.30.24301996; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
 be acquired automatically. Furthermore, models are easily over-fitted by selecting too many features,

- resulting in models that could not be used outside the strict inclusion criteria (Albahri et al., 2020;
- 84 Hooli and King, 2020; Wynants et al., 2020). Models developed on a population of PCR-tested
- 85 patients, cannot be used to guide clinicians to decide for PCR testing, as the clinical considerations to
- 86 request PCR testing are not taken into account. In addition, when volume and speed are important,
- 87 also composite models requiring data from other diagnostic tools like a CT scan (COVID-19 CO-
- 88 RADS classification) (Lessmann et al., 2021) or X-ray (Kurstjens et al., 2020) are hard to implement
- 89 in routine care.
- 90 In this study we report on the development and validation of a prediction model that, based on routine
- 91 laboratory tests, estimates the risks of a patient presenting at the ED for testing positive for COVID-
- 19. The model can be used during high and low prevalence ("waves") of COVID-19. Since the model
- 93 was successfully validated externally, it can be used clinically to reduce the number of PCR tests,
- 94 exclude COVID-19 in patients and identify patients with a high risk of being SARS-CoV-2 positive,
- 95 even if the patients are asymptomatic.

medRxiv preprint doi: https://doi.org/10.1101/2024.01.30.24301996; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 14 It is made available under a CC-BY 4.0 International license . 15 Methods

### 97 Study design

98 Routine laboratory results combined with age and gender from all patient presenting at the emergency 99 department (ED) of the Catharina Hospital Eindhoven from July 2019 to July 2020 were combined 100 with SARS-CoV-2 PCR test results in a development dataset. A model that could predict the presence 101 of a COVID-19 infection was fit to this dataset. Performance of the model was assessed by 1) internal 102 validation using bootstrapping, 2) temporal validation by using data from all patients presenting at the 103 ED of the Catharina Hospital from July 2020 to November 2020, and 3) external validation by using 104 data from the ED of three other hospitals in the Netherlands. The study was reviewed by the Medical 105 research Ethics Committees United (MEC-U) under study number W20.071, which confirmed that the 106 Medical Research Involving Human Subjects Act (In Dutch: WMO) does not apply to this study. The 107 study was thereafter reviewed and approved by the internal hospital review board.

108

#### 109 Development dataset

110 All ED patient presentations of the Catharina Hospital Eindhoven from July 2019 to July 2020 were 111 included in the development dataset, provided that routine laboratory testing had been requested by the 112 attending physician. The routine laboratory panel at the ED consists of 28 laboratory tests. However, 113 in some cases not all tests in the routine panel were requested or one or more quantitative results were 114 not available due to analytical interference (hemolysis, lipemia or icterus). Presentations with missing 115 values in the routine panel were excluded. Presentations with one or more extreme lab results (> 10116 times standard deviation) were also excluded. After the first case of COVID-19 in the Netherlands (28 117 February 2020) all patients with symptoms of COVID-19 (either fever and/or respiratory symptoms) 118 were subjected to nasopharyngeal PCR testing for SARS-CoV-2 RNA. PCR testing was performed by 119 commercial tests that were approved by the Dutch national institute of public health (RIVM). If a 120 patient had a positive PCR result in the past, subsequent presentations were excluded as re-121 presentations might be clinically different from de novo presentations.

medRxiv preprint doi: https://doi.org/10.1101/2024.01.30.24301996; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BV 4.0 International license The ED routine lab panel results were merged with SARS-CoV-2 PCR results if the underlying nose

122

123 or throat swap had been taken  $\leq 1$  day prior, or  $\leq 1$  week after initial blood withdrawal at the ED. If

- 124 multiple PCR tests were performed in this window and at least one PCR test was positive, the
- 125 presentation was labelled "PCR-positive". If all PCR test results in the time window were negative, the
- presentation was labelled as "PCR-negative". If no PCR tests were performed in the time window but 126
- 127 the presentation occurred after the first case of COVID-19 in the Netherlands, the presentation was
- 128 labelled as "Asymptomatic". All presentations before the first case in our center were labelled as "Pre-129 COVID-19".

130

#### 131 Laboratory tests

- 132 The routine laboratory panel consisted of hemocytometric and chemical analyses. In the Catharina
- 133 hospital, the hemocytometric tests were performed on Sysmex XN-10 instruments (Sysmex Corp.,
- 134 Kobe, Japan) and consisted of hemoglobin, hematocrit, erythrocytes, mean corpuscular volume
- 135 (MCV), mean cellular hemoglobin (MCH), mean cellular hemoglobin concentration (MCHC),
- 136 thrombocytes, leukocytes, neutrophils, eosinophils, basophils, lymphocytes and monocytes. The
- 137 chemical analyses were performed on a Cobas 8000 Pro (Roche Dx, Basel, Switzerland) instrument

138 and consisted of glucose, total bilirubin, aspartate aminotransferase (ASAT), alanine aminotransferase

- 139 (ALAT), lactate dehydrogenase (LD), creatine kinase (CK), alkaline phosphatase (ALP), gamma-
- 140 glutamyltransferase (gGT), blood urea nitrogen (BUN), creatinine, CKD-epi estimated glomerular
- 141 filtration rate (eGFR), potassium, sodium, chloride, albumin (bromocresol green) and C-reactive
- 142 protein (CRP). These results were combined with age and gender.

143

#### Modelling 144

145 All data were processed and analyzed in R version 4.0.3 (R Core Team, 2020). Laboratory results, combined with age and gender were used as covariates in the model. Cases were ED presentations 146 labelled as "PCR-positive", controls as "PCR-negative", "Asymptomatic" or "Pre-COVID-19". To 147

medRxiv preprint doi: https://doi.org/10.1101/2024.01.30.24301996; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
minimize additional missing data, all non-numeric results at the extremes of the measuring range, were
converted to numeric results by removing the "<" and ">" signs. For eGFR (CKD-epi) and CRP this
caused a discontinuous distribution. Therefore, instead of random sampling for eGFR (CKD-epi) and
CRP the raw precursor value was used instead of >90 ml/min/m<sup>2</sup> and <6 mg/L, respectively.</li>

152 Considering that laboratory results of bilirubin, ASAT, ALAT, LD, CK, AF and gGT can have heavy

153 (right) tailed distributions, which in turn impacts model predictions, these variables were transformed

154 logarithmically.

155 To achieve predictive accuracy, limit overfitting and emphasize sparsity, adaptive lasso regression was

156 chosen (Tibshirani, 1996; Zou, 2006). Prior to model fitting, covariates were scaled to zero mean and

157 unit variance, after model fitting coefficients were unscaled to obtain regression coefficients on the

158 original scale. In adaptive lasso, weights are applied to each of the covariates present in the lasso

159 constraint, the weight vector has to be calculated before the adaptive lasso regression is performed.

160 Due to multicollinearity between laboratory tests in the routine lab panel, weights in the adaptive lasso

161 were based on ridge regression estimates ( $\hat{\beta}_{ridge}$ ) as recommended by Zou (Zou, 2006). To obtain

162  $\hat{\beta}_{ridge}$  the optimal penalty ( $\lambda$ ) for the ridge regression was chosen using 10 fold cross-validation (CV)

163 with area under the ROC curve (AUC) as the loss function. The  $\lambda$  corresponding to the maximum

164 AUC was selected to obtain  $\hat{\beta}_{ridge}$ . The weight vector ( $\hat{w}$ ) was calculated by  $\hat{w} = 1/|\hat{\beta}_{ridge}|^2$ . This

165 weight vector was then used to fit an adaptive lasso regression where  $\lambda$  was chosen by the criterion  $\pm 1$ 

166 SE of the maximum AUC. All models were fitted using the glmnet-package (Friedman et al., 2010).

167 Since this is a retrospective case-control study, the sample prevalence may not reflect the true/current 168 prevalence, as is the case with COVID-19. Therefore the intercept term in the model must be adjusted 169 according to the actual prevalence (if known, or estimated) to obtain well-calibrated probabilities

(King and Zeng, 2001).

171

170

medRxiv preprint doi: https://doi.org/10.1101/2024.01.30.24301996; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

172 CoLab-score

173 Since manually updating the intercept term is not straightforward to implement in clinical practice, we developed the CoLab-score. The CoLab-score is a categorization of the linear predictor into a CoLab-174 175 score ranging from 0 to 5, where score 0 reflects low risk for COVID-19 and score 5 reflects high risk. 176 The CoLab-score is based on a fixed number needed to test of 15, this implies that one is willing to 177 test 15 patients to find one positive. A number needed to test of 15 corresponds to a threshold 178 probability of 1/15 = 0.067, on the linear predictor (or log-odds) scale, this corresponds to a threshold 179 of logit(0.067) = -2.639. This threshold is correct when the sample prevalence matches the actual 180 prevalence. In reality the prevalence of COVID-19 in the ED varies, therefore thresholds are 181 calculated for prevalence cut-points of 1%, 2%, 5%, 10% and 40% using the intercept adjustment 182 formula by King (King and Zeng, 2001). The intervals obtained through these breaks correspond to 183 CoLab-scores 5 to 0, respectively. The CoLab-score can thus be used as a "prevalence-dependent 184 binary classification" (either positive or negative). If COVID-19 prevalence at the ED in the previous 185 week is <1%, only CoLab-score 5 should be classified as positive and CoLab-score 0 till 4 as negative. 186 If prevalence is 1% - 2%, CoLab-score 4 and 5 should be classified as positive and 1 - 3 negative. 187 Similarly, with a prevalence of 2-5% the split is between CoLab-score 2 and 3 and with prevalence 188 of 5 - 10% between CoLab-score 1 - 2. If the prevalence is higher than 10% only CoLab-score 0 is 189 classified as negative. Using the CoLab-score in this fashion, aims to preserve a number need to test of 190 15.

191

#### 192 Internal validation

To assess model performance while taking overfitting into account, bootstrapping was performed.
1000 bootstrap samples were generated from the original data. On each bootstrap sample, the full
model fitting procedure and CoLab-score conversion were performed. Optimism adjusted performance
measures of the CoLab-score were obtained by applying the 0.632 bootstrap rule to the in-sample and
out-of-bag-sample performance (Efron, 1983). Performance measures included, AUC, sensitivity,
specificity, positive predictive value (PPV) and negative predictive value (NPV) of each CoLab-score.

medRxiv preprint doi: https://doi.org/10.1101/2024.01.30.24301996; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license. The pROC-package was used to calculate performance measures (Robin et al., 2011). The

199

200 performance of the prevalence dependent binary CoLab-classification was evaluated in terms of 201 overall sensitivity and specificity, and potential reduction in the number of PCR-tests. Although the 202 full inclusion period from July 2019 to July 2020 was used for model fitting, the performance was evaluated on the period starting from the first COVID-19 infection (24<sup>th</sup> of February 2020) to July 203 204 2020. This was done to obtain performance measures that would reflect real world performance during 205 COVID-19 waves.

206

#### 207 Temporal validation

208 For temporal validation, results from our center were prospectively analyzed from July 2020 to 209 November 2020. During this period, a second wave of COVID-19 infections developed. In this period 210 there was also more widespread external PCR testing by municipal health services (In Dutch: GGD). 211 Since the results of external conducted PCR tests were not available to our study, the outcome in the 212 temporal validation cohort was chosen as a composite of the hospital registration of a confirmed 213 COVID-19 infection or at least one positive PCR test results in the hospital (with the same time 214 window as described above). The temporal validation consisted of assessing the AUC, sensitivity, 215 specificity, PPV and NPV of each CoLab-score threshold. Calibration was assessed graphically by 216 converting the CoLab-linear predictor to the predicted probability (through the inverse logit function) 217 and plotting the proportion of observed outcomes versus expected probabilities. The rms-package was 218 used to generate calibration plots (Harrell Jr, 2021).

219

#### 220 External validation

221 For the external validation, several centers in the Netherlands were approached and asked if they 222 collected the required panel of laboratory tests and had access to SARS-CoV-2 PCR test results. Seven 223 centers responded and the three centers with the least inclusion bias (i.e. measuring routinely all 224 laboratory tests underlying the CoLab-score for large unselected patient groups) were Gelre Hospitals

medRxiv preprint doi: https://doi.org/10.1101/2024.01.30.24301996; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (center 1), Atalmedial Diagnostic Centers, location Alrijne Hospital Leiderdorp (center 2) and

- 225
- 226 Zuyderland Medical Center (center 3). The hematological parameters were measured with Sysmex
- 227 XN10/XN20 (center 1), CELL-DYN-Sapphire (Abbott Laboratories) (center 2) and Sysmex XN10
- 228 instruments (center 3). The clinical chemistry parameters were measured with Architect
- 229 c14100/c160000 (Abbott Laboratories) (center 1), Architect ci4100 (Abbott Laboratories) (center 2)
- 230 and Cobas 8000 instruments (Roche Dx) (center 3). The external validation was similar to the
- 231 temporal validation and consisted of assessing the AUC sensitivity, specificity, PPV and NPV of each
- 232 CoLab-score threshold. Calibration was assessed graphically analogous to the temporal validation
- 233 dataset. In addition, the distributions of the variables in the CoLab-scores was plotted for all control
- 234 (i.e. negative) patients to determine if there were any systematic differences that could cause bias in
- 235 the CoLab-score predictions.

medRxiv preprint doi: https://doi.org/10.1101/2024.01.30.24301996; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

#### 236 **Results**

#### 237 Development dataset

- For model building, 12.879 emergency department (ED) presentations of 10.327 patients from July
- 239 2019 to July 2020 were included. After excluding cases with an incomplete lab panel, patient
- 240 presentations that occurred after a positive PCR test in the past (re-presentations) and presentations
- with extreme values (>10 times standard deviation) in any of the lab results, 10.417 presentations of
- 242 8610 patients remained (Figure 1A).
- 243

#### Figure 1: Inclusion flow of patients in the development (A) and temporal validation (B) dataset.

- 245 All patient admissions with routine venous blood sampling at the emergency department (ED) were
- 246 included. For the development dataset, completeness of the lab panel was assessed for all the 29
- 247 laboratory tests (see Table 1), for the temporal validation dataset this was only necessary for 10
- 248 laboratory tests (see Table 2). The major causes of missingness are described in the text. In the
- 249 development dataset, presentations with extreme values (>10 SD) were excluded. The same limits
- 250 *were applied to the temporal validation dataset (see Table 2 for limits).*
- 251

|                      | Pre-COVID-19<br>(N = 5890) | Asymptomatic<br>(N = 3303) | PCR negative<br>(N = 945) | PCR positive<br>(N = 279) |
|----------------------|----------------------------|----------------------------|---------------------------|---------------------------|
| Age in years         | 61 (21)                    | 60 (21)                    | 66 (18)                   | 69 (15)                   |
| Female gender        | 2909 (49.4 %)              | 1659 (50.2 %)              | 466 (49.3 %)              | 95 (34.1 %)               |
| Hemoglobin in mmol/L | 8.2 (1.3)                  | 8.3 (1.3)                  | 8.2 (1.4)                 | 8.6 (1.1)                 |
| Hematocrit in L/L    | 0.403 (0.059)              | 0.405 (0.056)              | 0.405 (0.062)             | 0.417 (0.047)             |
| Erythrocytes /pL     | 4.41 (0.69)                | 4.43 (0.66)                | 4.41 (0.72)               | 4.61 (0.60)               |
| MCV in fl            | 91.8 (6.4)                 | 91.9 (6.1)                 | 92.4 (6.7)                | 90.7 (5.5)                |
| MCH in mmol          | 1.859 (0.157)              | 1.876 (0.150)              | 1.874 (0.172)             | 1.869 (0.141)             |
| MCHC in mmol/L       | 20.2 (0.9)                 | 20.4 (0.9)                 | 20.3 (1.0)                | 20.6 (0.8)                |
| Thrombocytes /nL     | 263 (99)                   | 266 (100)                  | 269 (105)                 | 217 (123)                 |
| Leukocytes /nL       | 9.30 [7.06, 12.16]         | 8.92 [7.01, 11.89]         | 9.66 [7.17, 12.94]        | 6.33 [4.74, 8.48]         |
| Neutrophils /nL      | 6.62 [4.51, 9.53]          | 6.10 [4.42, 8.94]          | 7.01 [4.79, 10.02]        | 4.71 [3.30, 6.94]         |
| Eosinophils /nL      | 0.09 [0.03, 0.17]          | 0.09 [0.03, 0.18]          | 0.08 [0.02, 0.17]         | 0.00 [0.00, 0.02]         |
| Basophils /nL        | 0.04 [0.02, 0.05]          | 0.04 [0.02, 0.05]          | 0.04 [0.02, 0.05]         | 0.01 [0.01, 0.02]         |
| Lymphocytes/nL       | 1.47 [0.93, 2.13]          | 1.56 [1.05, 2.18]          | 1.31 [0.80, 2.03]         | 0.86 [0.59, 1.21]         |
| Monocytes /nL        | 0.70 [0.52, 0.93]          | 0.69 [0.52, 0.91]          | 0.74 [0.54, 1.01]         | 0.45 [0.32, 0.64]         |
| Glucose in mmol/L    | 6.76 [5.83, 8.39]          | 6.68 [5.76, 8.14]          | 6.98 [5.95, 8.85]         | 6.77 [5.98, 8.48]         |
| Bilirubin in µmol/L  | 7.5 [5.0, 11.6]            | 7.4 [5.1, 10.9]            | 8.3 [5.6, 12.4]           | 8.2 [6.3, 11.4]           |
| ASAT in U/L          | 24.0 [19.1, 32.2]          | 26.5 [21.6, 35.1]          | 27.7 [21.7, 39.2]         | 40.7 [30.2, 57.2]         |

medRxiv preprint doi: https://doi.org/10.1101/2024.01.30.24301996; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

|                                  | Pre-COVID-19       | Asymptomatic       | PCR negative       | PCR positive      |
|----------------------------------|--------------------|--------------------|--------------------|-------------------|
|                                  | (N = 5890)         | (N = 3303)         | (N = 945)          | (N = 279)         |
| ALAT in U/L                      | 24.3 [17.8, 35.3]  | 25.3 [18.4, 36.2]  | 25.7 [18.4, 40.0]  | 33.7 [23.3, 50.0] |
| LD in U/L                        | 201 [173, 240]     | 198 [170, 236]     | 215 [178, 263]     | 300 [238, 403]    |
| CK in U/L                        | 82 [51, 134]       | 83 [52, 136]       | 76 [51, 125]       | 124 [62, 222]     |
| AF in IU/L                       | 83.0 [68.0, 105.0] | 81.0 [65.8, 102.5] | 86.9 [67.9, 110.0] | 71.0 [58.8, 85.0] |
| gGT in U/L                       | 27.0 [17.0, 53.0]  | 28.4 [18.4, 50.5]  | 37.0 [22.4, 68.9]  | 42.0 [28.0, 83.5] |
| BUN in mmol/L                    | 5.7 [4.3, 8.0]     | 5.8 [4.3, 7.8]     | 6.2 [4.6, 9.4]     | 6.1 [4.7, 8.9]    |
| CKD-epi in ml/min/m <sup>2</sup> | 80.9 [58.0, 99.1]  | 85.0 [63.5, 103.3] | 79.1 [52.1, 96.6]  | 76.6 [54.9, 91.2] |
| Creatinine in µmol/L             | 79 [64, 100]       | 74 [61, 94]        | 78 [62, 105]       | 82 [68, 104]      |
| Potassium in mmol/L              | 4.06 (0.50)        | 4.03 (0.49)        | 4.07 (0.55)        | 3.91 (0.47)       |
| Sodium in mmol/L                 | 139.2 (4.0)        | 138.5 (3.9)        | 138.0 (4.3)        | 136.4 (4.1)       |
| Chloride in mmol/L               | 104.4 (4.6)        | 103.8 (4.5)        | 102.9 (4.8)        | 101.6 (4.4)       |
| Albumin in g/L                   | 42.4 (4.9)         | 42.3 (4.5)         | 40.8 (4.8)         | 38.4 (3.8)        |
| CRP in mg/L                      | 8 [2, 41]          | 5 [1, 30]          | 18 [3, 69]         | 77 [37, 136]      |

<sup>252</sup> 

#### **Table 1: Descriptive statistics of development dataset and laboratory concentrations.**

254 Shown are the laboratory tests routinely requested at ED presentation and their mean/median results

255 (in the development dataset) for the presentations before the first COVID-19 patient in the

256 Netherlands ("Pre-COVID-19"), presentations thereafter that were not tested for COVID-19

257 ("Asymptomatic"), tested negatively ("PCR negative") and tested positive ("PCR positive"). For

258 results with normal distributions, the mean value and standard deviation (in round brackets) are

shown. For results that have skewed or heavy tailed distributions, the median value and the

260 interquartile range is shown [in squared brackets]. Dark grey marked figures indicate a clinically

261 relevant difference from the Pre-COVID-19 category (based on the total allowable error (Ricós et al.,

262 1999)).

263

#### 264 Descriptive statistics of ED presentations are shown in **Table 1**. Presentations were stratified into four

265 categories: "Pre-COVID-19" consists of all ED presentations before the first case of COVID-19 in our

266 center (N = 5890). This period also includes a winter flu-season. The category "Asymptomatic"

267 consists of ED presentations (N = 3303) after the first case of COVID-19, but who were not subjected

to PCR testing. Finally, presentations tested for SARS-CoV-2 were categorized depending on the

result as "PCR negative" (N= 945) or "PCR positive" (N= 279). In the latter category, 91% (95% CI:

- 270 88 to 94%) of the cases were tested positive in their first PCR. The remaining 24 patients were
- positive in their second (N = 18), third (N = 5) or fourth (N = 1) PCR.

medRxiv preprint doi: https://doi.org/10.1101/2024.01.30.24301996; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

- Table 1 shows the mean/median concentrations of the ED laboratory tests for each category.
- 273 Concentrations that clinically differed from the Pre-COVID-19 category are marked in grey. As
- 274 expected, patients tested positive for SARS-CoV-2 showed multiple clinically relevant differences.
- 275 Interestingly, some differences (like increased CRP and gGT) were although to a lesser extent also
- 276 present in the COVID-19 negative-tested patient group.
- 277

#### 278 CoLab-score

- 279 The model obtained through adaptive lasso regression contained eleven variables, which are depicted
- 280 with their regression coefficients (weights) in **Table 2**. A larger  $\beta$ -coefficient does not imply that a
- 281 variable is more important in predicting the odds of testing positive for SARS-CoV-2, since the
- 282 coefficients are unscaled after model fitting and variables are on different scales. Therefore, the
- 283 relative importance is calculated based on scaled coefficients. The absolute basophil count has the
- 284 highest relative weight, followed by eosinophil count.
- 285

| Variable                                 | β        | Exclusion limit        | Relative importance |
|--|----------|------------------------|---------------------|
| Intercept                                | -6.885   |                        | -                   |
| Erythrocytes /pL                         | 0.9379   | Erythrocytes < 2.9 /pL | 52 %                |
| Leukocytes /nL                           | -0.1298  |                        | 46 %                |
| Eosinophils /nL                          | -6.834   |                        | 86 %                |
| Basophils /nL                            | -47.70   | Basophils >0.33 /nL    | 100 %               |
| log <sub>10</sub> of Bilirubin in µmol/L | -1.142   | Bilirubin >169 µmol/L  | 26 %                |
| log <sub>10</sub> of LD in U/L           | 5.369    | LD >1564 U/L           | 58 %                |
| log₁₀ of AF in IU/L                      | -3.114   | AF >1000 IU/L          | 45 %                |
| log₁₀ of gGT in U/L                      | 0.3605   | gGT >1611 U/L          | 11 %                |
| Albumin in g/L                           | -0.1156  |                        | 45 %                |
| CRP in mg/L                              | 0.002560 |                        | 15 %                |
| Age in years                             | 0.002275 |                        | 4 %                 |

286

### 287 Table 2: Calculation of the CoLab-linear predictor (LP).

- 288 The CoLab-linear predictor (LP) is calculated by summing the intercept and the products of the 11
- variables with their corresponding coefficients ( $\beta$ 's). CoLab-LP =  $-6.885 + [erythrocytes] \times 0.9379$
- $290 \qquad [leukocytes] \times 0.1298 [eosinophils] \times 6.834 [basophils] \times 47.7 log10([bilirubin]) \times 1.142 + 1.$

medRxiv preprint doi: https://doi.org/10.1101/2024.01.30.24301996; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 291  $log10([LD]) \times 5.369 - log10([AFf]) \times 3.114 + log10([gGT]) \times 0.3605 - [albiumin] \times 0.1156 + [CRP]$ 

- 292  $\times 0.02560 + [age] \times 0.002275$ . The LP can be converted into a CoLab-score (see Figure 2) or into a
- 293 probability if the prevalence is known or estimated (see details in Appendix A). The CoLab-score is
- 294 not valid if any of the variables exceed the limits in the third column.

295

- 296 Figure 2: Probability density plot of the CoLab-linear predictor.
- 297 The probability density plots for COVID (dark grey) and non-COVID patients (light grey) are plotted
- against the linear predictor (see table 2). The CoLab-score cut-offs (-5.83, -4.02, -3.29, -2.34 and
- 299 –1.64) are depicted with vertical dashed lines. The white-boxed numbers (between the cut-offs)
- 300 represent the corresponding CoLab-score. Note that while the area under both curves is identical
- 301 (since these are probability density functions), in absolute numbers the "negative or untested"-group
- 302 *is about 36 times larger than the PCR positive group.*

303

304 As shown in Figure 2, the linear predictor clearly discriminates between COVID-19 and non-COVID-305 19. Note that in this figure, the area under both curves is equal since these are probability density 306 functions, in reality the weekly COVID-19 prevalence at the ED varies from <1% to 36% and hence 307 the number of presentations in the PCR positive group. Therefore, the linear predictor was converted 308 to CoLab-scores 0-5 (Figure 2). Subsequently, the actual prevalence of the previous week was used 309 to obtain a threshold above which patients should be tested, this is hereafter referred to as the 310 "prevalence-dependent binary classification". CoLab-scores above the prevalence-dependent cut-off 311 value, are classified as "positive" and warrant PCR testing, while CoLab-scores equal to or below the 312 cut-off value (= "negative") discourage PCR testing. If the prevalence is not known, the CoLab-score 313 can be used as-is, where patients with a CoLab-score of 0 can be considered non-COVID-19 and 314 patients with a score 5 as highly suspicious for COVID-19.

315

medRxiv preprint doi: https://doi.org/10.1101/2024.01.30.24301996; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

- 316 Internal validation
- 317 The model was validated on the period starting from the first COVID-19 infection to July 2020, in this
- 318 period the mean prevalence was 7.2%. The AUC of the CoLab-score is 0.930 (95% CI: 0.909 to
- 319 0.945). A CoLab-score of 0 has a negative predictive value (NPV) of 0.997 (95% CI: 0.994 to 0.999,
- **Table 3**), one third (38.4%, 95% CI: 26.4 to 48.4%) of all ED presentations were assigned this score
- and can therefore be safely excluded. Conversely, 6.2% (95% CI: 6.3 to 7.2%) of the ED patients have
- 322 a CoLab-score 5. Given the high positive predictive value (PPV) of this category (0.682, 95% CI:
- 323 0.622 to 0.740), subsequent PCR testing is advised.

324

| CoLab<br>Cut-off | Sensitivity           | Specificity           | PPV                    | NPV                   | %                  |
|------------------|-----------------------|-----------------------|------------------------|-----------------------|--------------------|
| 0                | 0.984 (0.970 - 0.991) | 0.411 (0.285 - 0.520) | 0.115 (0.0932 - 0.141) | 0.997 (0.994 - 0.999) | 38.4 (26.4 - 48.4) |
| ≤ 1              | 0.909 (0.886 - 0.943) | 0.793 (0.744 - 0.826) | 0.255 (0.207 - 0.299)  | 0.991 (0.989 - 0.995) | 74.4 (69.4 - 77.4) |
| ≤2               | 0.859 (0.811 - 0.889) | 0.887 (0.866 - 0.901) | 0.371 (0.317 - 0.414)  | 0.988 (0.983 - 0.991) | 83.2 (82.2 - 85.2) |
| ≤ 3              | 0.750 (0.700 - 0.810) | 0.953 (0.944 - 0.959) | 0.551 (0.494 - 0.601)  | 0.980 (0.975 - 0.985) | 90.1 (89.1 - 91.1) |
| ≤ 4              | 0.608 (0.522 - 0.685) | 0.978 (0.973 - 0.983) | 0.682 (0.622 - 0.740)  | 0.970 (0.962 - 0.977) | 93.8 (92.8 - 93.8) |
| Pos/Neg          | 0.923 (0.879 - 0.944) | 0.816 (0.756 - 0.842) | 0.310 (0.246 - 0.352)  | 0.992 (0.987 - 0.994) | -                  |
| 325              |                       |                       |                        |                       |                    |

326 **Table 3: Diagnostic performance CoLab-score in the development dataset.** 

327 The development dataset was internally validation for the period March 2020 - July 2020 (N =

328 4.527). Sensitivities, specificities, positive predictive values (PPV), negative predictive values (NPV)

and fraction of patients (%) are shown for fixed cut-offs (CoLab-score 0 till  $\leq 4$ ) and the prevalence

330 dependent binary CoLab-classification (Pos/Neg). The numbers in round brackets represent the 95%

331 confidence intervals. The first column defines the threshold above which CoLab-score a patient is

332 considered positive.

333

For CoLab-scores 1 - 4, the threshold to guide PCR testing is dependent on COVID-19 prevalence.

335 Therefore, the CoLab-score was dichotomized as positive or negative, based on the prevalence of the

previous week. As shown in **Table 3**, the sensitivity of this binary CoLab-classification (0.923, 95%

337 CI: 0.879 to 0.944) is similar to singular PCR testing (0.91, 95% CI: 0.88 to 0.94), and has a NPV of

medRxiv preprint doi: https://doi.org/10.1101/2024.01.30.24301996; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 338 0.992 (95% CI: 0.987 to 0.994). Therefore, the CoLab-Score and the prevalence dependent binary

339 classification could be used to guide PCR testing when rapid PCR testing is not available or test

- 340 capacity is limited. Using the CoLab-score retrospectively on the development dataset to guide PCR
- testing, 92.3% (95% CI: 87.9 to 94.4%) of the COVID-19 patients could have been identified with

342 30.5% (95% CI: 14.5% to 37.6%) fewer PCR test. The largest reductions are seen in periods with low

- 343 or rapidly decreasing prevalence, when more than half of the PCR tests may be superfluous (Figure
- 344 **3**).

345

#### **Figure 3: CoLab-guided PCR testing versus routine practice.**

347 The black bars represent the number of SARS-CoV-2-PCR tests performed on a weekly basis in the

- 348 Catharina Hospital. The grey bars represent the number of positives by using the prevalence
- 349 dependent binary CoLab-classification (in this setting the COVID-19 ED prevalence of the previous
- 350 week determines the threshold above which a CoLab-score is considered positive in the week
- 351 thereafter). If PCR testing was performed for all CoLab-positives, the sensitivity would not by lower
- 352 than a single PCR-test (see **Table 3**) and this would result a reduction in the number of PCR tests.

353

#### 354 Temporal validation

355 As the CoLab-score was developed in our center after the first COVID-19-wave in the Netherlands,

the performance was evaluated in our center during the subsequent second wave. In the Netherlands,

the second wave started in August 2020. During this period lab results from 5100 ED presentations

358 were collected. After applying the inclusion flow as shown in Figure 1B, 4.333 presentations

remained, of which 165 were associated with a COVID-19 infection.

360 The mean prevalence in this period was 3.8%, which is approximately half of the prevalence during

the first period. The AUC of the CoLab-score in the temporal validation set is 0.895 (95% CI: 0.866 to

- 362 0.932). The performance in terms of specificity and NPV is similar to the development cohort,
- 363 whereas the sensitivity and PPV are slightly lower, although 95% CIs overlap (see Tables 3 and 4). In

medRxiv preprint doi: https://doi.org/10.1101/2024.01.30.24301996; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

| 364  | terms of calibration, the observed fraction of COVID-19 positives appears slightly higher than  |
|--|---|
| 365  | expected (Figure 6A). When using the prevalence-dependent binary classification, the sensitivity is   |
| 366  | 0.868 and the NPV is 0.993 (Table 4), which is somewhat lower than the development dataset.   |
| 367  | Based on these findings, we investigated the relation between the CoLab-linear predictor and duration   |
| 368  | of COVID-19-related symptoms at ED presentation in the "PCR positive" presentations of both the   |
| 369  | internal and temporal validation datasets. As shown in Figure 4, the CoLab-linear predictor increases   |
| 370  | with the duration of symptoms and gradually decreases after day 7. As a consequence, some COVID-  |
| 371  | 19 patients with early or late presentation after onset of symptoms are missed by the CoLab-score.  |
| 372  | Optimal performance of the CoLab-score is achieved when the onset of symptoms is $> 1$ and $< 10$   |
| 373  | days prior to ED presentation.  |
|  |   |
| 374  |   |
| 374<br>375   | Figure 4: Association between the CoLab-linear predictor and the duration of COVID-19-  |
| <ul><li>374</li><li>375</li><li>376</li></ul>  | Figure 4: Association between the CoLab-linear predictor and the duration of COVID-19-<br>related symptoms.   |
| <ul><li>374</li><li>375</li><li>376</li><li>377</li></ul>  | Figure 4: Association between the CoLab-linear predictor and the duration of COVID-19-         related symptoms.         For all PCR-positive ED presentations in the development and temporal validation dataset, the  |
| <ul> <li>374</li> <li>375</li> <li>376</li> <li>377</li> <li>378</li> </ul>  | Figure 4: Association between the CoLab-linear predictor and the duration of COVID-19-         related symptoms.         For all PCR-positive ED presentations in the development and temporal validation dataset, the         CoLab-linear predict is plotted against the duration of COVID-related symptoms as registered in the  |
| <ul> <li>374</li> <li>375</li> <li>376</li> <li>377</li> <li>378</li> <li>379</li> </ul>   | Figure 4: Association between the CoLab-linear predictor and the duration of COVID-19-         related symptoms.         For all PCR-positive ED presentations in the development and temporal validation dataset, the         CoLab-linear predict is plotted against the duration of COVID-related symptoms as registered in the         electronic patient records. Patients with unknown duration are not plotted. Patients without symptoms  |
| <ul> <li>374</li> <li>375</li> <li>376</li> <li>377</li> <li>378</li> <li>379</li> <li>380</li> </ul>  | Figure 4: Association between the CoLab-linear predictor and the duration of COVID-19-         related symptoms.         For all PCR-positive ED presentations in the development and temporal validation dataset, the         CoLab-linear predict is plotted against the duration of COVID-related symptoms as registered in the         electronic patient records. Patients with unknown duration are not plotted. Patients without symptoms         were plotted at 0 days. The solid horizontal lines represent the CoLab-score thresholds, the dashed  |
| <ul> <li>374</li> <li>375</li> <li>376</li> <li>377</li> <li>378</li> <li>379</li> <li>380</li> <li>381</li> </ul>                           | Figure 4: Association between the CoLab-linear predictor and the duration of COVID-19-<br>related symptoms.<br>For all PCR-positive ED presentations in the development and temporal validation dataset, the<br>CoLab-linear predict is plotted against the duration of COVID-related symptoms as registered in the<br>electronic patient records. Patients with unknown duration are not plotted. Patients without symptoms<br>were plotted at 0 days. The solid horizontal lines represent the CoLab-score thresholds, the dashed<br>line is a LOESS regression curve with 95% CI. As the duration of symptoms is an integer, some  |
| <ul> <li>374</li> <li>375</li> <li>376</li> <li>377</li> <li>378</li> <li>379</li> <li>380</li> <li>381</li> <li>382</li> </ul>              | Figure 4: Association between the CoLab-linear predictor and the duration of COVID-19-<br>related symptoms.<br>For all PCR-positive ED presentations in the development and temporal validation dataset, the<br>CoLab-linear predict is plotted against the duration of COVID-related symptoms as registered in the<br>electronic patient records. Patients with unknown duration are not plotted. Patients without symptoms<br>were plotted at 0 days. The solid horizontal lines represent the CoLab-score thresholds, the dashed<br>line is a LOESS regression curve with 95% CI. As the duration of symptoms is an integer, some<br>random jitter was added to the days, for visualization purposes. Note that only the first 14 days are                         |
| <ul> <li>374</li> <li>375</li> <li>376</li> <li>377</li> <li>378</li> <li>379</li> <li>380</li> <li>381</li> <li>382</li> <li>383</li> </ul> | Figure 4: Association between the CoLab-linear predictor and the duration of COVID-19-<br>related symptoms.<br>For all PCR-positive ED presentations in the development and temporal validation dataset, the<br>CoLab-linear predict is plotted against the duration of COVID-related symptoms as registered in the<br>electronic patient records. Patients with unknown duration are not plotted. Patients without symptoms<br>were plotted at 0 days. The solid horizontal lines represent the CoLab-score thresholds, the dashed<br>line is a LOESS regression curve with 95% CI. As the duration of symptoms is an integer, some<br>random jitter was added to the days, for visualization purposes. Note that only the first 14 days are<br>shown in this graph. |

384

## 385 External validation

For external validation, data obtained from three other centers were used. The data were processed
analogous to the development dataset. The inclusion flow is summarized in Figure 5.

388

medRxiv preprint doi: https://doi.org/10.1101/2024.01.30.24301996; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Figure 5: Inclusion flow of ED patients in three external centers.

389

390 All emergency department (ED) presentations with routine venous blood sampling were included.

391 Missingness of lab panels was assessed for the 11 variables in the CoLab-score (see Table 2). Re-

392 presentations after a positive PCR result or clinical COVID-19 registration were excluded as

393 "previous COVID-19+". Presentations with any laboratory result above the limits of the CoLab-score

394 (see Table 2) were excluded.

395

396 The large number of patients that are excluded in the first step (incomplete laboratory panel) in center 397 1 and center 2 is due to the fact that only ED presentations for internal medicine were tested for all 10 398 laboratory tests of the CoLab-score. The ED lab panel of other disciplines (e.g. urology, surgery or 399 pediatrics) differed and did not contain the required tests. Nevertheless, the majority of COVID-19 ED 400 presentations were examined by clinicians of internal medicine, which is reflected by the low number 401 of PCR-positive patients excluded. Other causes of missing lab results were mainly due to assay 402 interference. COVID-19 prevalence differed between the three centers (4.0%, 3.4% and 9.5% 403 respectively) and was lower in centers 1 and 2, and higher in center 3 than the internal validation 404 prevalence. The AUC's of the CoLab-score are 0.904 (95% CI: 0.866 to 0.942), 0.886 (95% CI: 0.851 405 - 0.922) and 0.891 (95% CI: 0.872 - 0.909), for centers 1, 2, and 3 respectively. 406 Performance in terms of sensitivity and specificity is shown in Table 4. Also the PPVs and NPVs are 407 shown, although these are largely dependent on prevalence. Although the sensitivity of the prevalence 408 dependent binary CoLab-classification in some centers is somewhat lower than in the development 409 and temporal dataset, the sensitivity of CoLab-score 0 in all centers is  $\geq 0.96$ . Therefore, the NPV of 410 CoLab-score 0 was more than 99%. However, when only presentations were taken into account with duration of symptoms >1 and < 10 days prior to presentation, the NPV for all patients with CoLab-411 412 score 0 was >99.8% (**Table 4**).

medRxiv preprint doi: https://doi.org/10.1101/2024.01.30.24301996; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Calibration plots for external centers are shown in **Figure 6B-D**, the observed fraction of COVID-19

- 413
- 414 positives is slightly lower than expected in centers 1 and 2. For center 3, low probabilities appear
- 415 slightly underestimated and high probabilities slightly overestimated.

#### 416

| CoLab | Validation | Sens. | Spec. | PPV   | NPV   | TP  | TN    | FP   | FN     | %  |
|-------|------------|-------|-------|-------|-------|-----|-------|------|--------|----|
| Score | set        |       |       |       |       |     |       |      |        |    |
|       | Temporal   | 0.958 | 0.410 | 0.060 | 0.996 | 158 | 1708  | 2460 | 7 (2)  | 40 |
| 0     | Center 1   | 1.000 | 0.333 | 0.059 | 1.000 | 52  | 410   | 822  | 0 (0)  | 32 |
| 0     | Center 2   | 0.960 | 0.352 | 0.050 | 0.996 | 95  | 985   | 1815 | 4 (2)  | 34 |
|       | Center 3   | 0.973 | 0.322 | 0.131 | 0.991 | 327 | 1034  | 2175 | 9 (5)  | 29 |
|       | Combined   | 0.969 | 0.363 | 0.080 | 0.995 | 632 | 4137  | 7272 | 20 (9) | 34 |
|       | Temporal   | 0.867 | 0.777 | 0.133 | 0.993 | 143 | 3239  | 929  | 22     | 75 |
| <1    | Center 1   | 0.923 | 0.696 | 0.113 | 0.995 | 48  | 857   | 375  | 4      | 67 |
|       | Center 2   | 0.929 | 0.680 | 0.093 | 0.996 | 92  | 1905  | 895  | 7      | 66 |
|       | Center 3   | 0.917 | 0.675 | 0.228 | 0.987 | 308 | 2167  | 1042 | 28     | 62 |
|       | Combined   | 0.906 | 0.716 | 0.154 | 0.993 | 591 | 8168  | 3241 | 61     | 68 |
|       | Temporal   | 0.776 | 0.885 | 0.211 | 0.990 | 128 | 3688  | 480  | 37     | 86 |
|       | Center 1   | 0.808 | 0.812 | 0.154 | 0.990 | 42  | 1001  | 231  | 10     | 79 |
| ≤2    | Center 2   | 0.869 | 0.802 | 0.134 | 0.994 | 86  | 2246  | 554  | 13     | 78 |
|       | Center 3   | 0.893 | 0.795 | 0.313 | 0.986 | 300 | 2552  | 657  | 36     | 73 |
|       | Combined   | 0.853 | 0.832 | 0.224 | 0.990 | 556 | 9487  | 1922 | 96     | 79 |
|       | Temporal   | 0.648 | 0.956 | 0.368 | 0.986 | 107 | 3984  | 184  | 58     | 93 |
| <3    | Center 1   | 0.750 | 0.910 | 0.260 | 0.989 | 39  | 1121  | 111  | 13     | 88 |
| 20    | Center 2   | 0.687 | 0.899 | 0.193 | 0.988 | 68  | 2516  | 284  | 31     | 88 |
|       | Center 3   | 0.768 | 0.888 | 0.417 | 0.973 | 258 | 2848  | 361  | 78     | 83 |
|       | Combined   | 0.724 | 0.918 | 0.334 | 0.983 | 472 | 10469 | 940  | 180    | 88 |
|       | Temporal   | 0.509 | 0.981 | 0.519 | 0.981 | 84  | 4090  | 78   | 81     | 96 |
| <1    | Center 1   | 0.654 | 0.952 | 0.366 | 0.985 | 34  | 1173  | 59   | 18     | 93 |
| 24    | Center 2   | 0.556 | 0.953 | 0.294 | 0.984 | 55  | 2668  | 132  | 44     | 94 |
|       | Center 3   | 0.667 | 0.931 | 0.502 | 0.964 | 224 | 2987  | 222  | 112    | 87 |
|       | Combined   | 0.609 | 0.957 | 0.447 | 0.977 | 397 | 10918 | 491  | 255    | 93 |
|       |            |       |       |       |       |     |       |      |        |    |
|       | Temporal   | 0.865 | 0.867 | 0.217 | 0.993 | 135 | 3189  | 488  | 21     | -  |
| Pos / | Center 1   | 0.941 | 0.824 | 0.191 | 0.997 | 48  | 948   | 203  | 3      | -  |
| Neg   | Center 2   | 0.857 | 0.861 | 0.193 | 0.994 | 84  | 2179  | 351  | 14     | -  |
| -     | Center 3   | 0.899 | 0.571 | 0.230 | 0.976 | 295 | 1314  | 988  | 33     | -  |
|       | Combined   | 0.883 | 0.801 | 0.216 | 0.991 | 567 | 8277  | 2054 | 75     | -  |

417

#### 418 Table 4: Diagnostic performance of the CoLab-score in the validation dataset (temporal) and 419 three external hospitals. 420 Sensitivities (sens.), specificities (spec.), positive predicting values (PPV), negative predicting values 421 (NPV), true positives (TP), true negatives (TN), false positives (FP) and false negatives (FN) are shown 422 for fixed cut-offs (CoLab-score 0 till $\leq$ 4) and the prevalence dependent binary CoLab-classification 423 (Pos/Neg). In the last column the fraction of patients at or below the cut-off are shown. For CoLab-

medRxiv preprint doi: https://doi.org/10.1101/2024.01.30.24301996; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

```
424 score 0, the numbers with round brackets indicate the number of false negatives when only patients with
```

425 symptom duration >1 and <10 days are taken into account. Note that "0" lists the sensitivity and NPV

426 of CoLab-score 0 and " $\leq 4$ " lists the specificity and PPV of CoLab-score 5.

427

# Figure 6: CoLab-score calibration plots of the temporal validation (A), external validation center 1 (B), external validation center 2 (C) and external validation center 3 (D).

430 In the calibration plots, the proportion of observed COVID-19 positives versus expected probabilities 431 are plotted. Observations are grouped with an average of 150 observations per group. The expected 432 probabilities follow from applying the inverse logit function to the CoLab-linear predictor calculated 433 from Table 2. If the observed proportion in an external dataset is lower than the expected proportion, 434 this means risks are over-estimated, if the observed fraction is higher, risks are under-estimated. Ideally, 435 observed proportions are equal to expected proportions, this ideal-calibration-line is shown as a straight line through the origin with a slope of 1. The logistic calibration line is a logistic regression fit 436 of the predicted probabilities. [Intercept, slope] for plots A-D: A [0.22, 0.92], B [-0.39, 0.92], C [-0.76, 437 438 0.77], D [0.08, 0.79]. Although no validation datasets show perfect calibration, this is the result of 439 differences in COVID-19 prevalence in each center and differences in calibration of laboratory 440 equipment (see Supplemental Figure 6).

441

#### 442 Supplemental Figure 6: Probability density plots of laboratory parameters.

Probability density plots are shown for all control patients of the development dataset and the three
external centers. Ideally all distributions should overlap since this implies that control patient
populations are most likely similar in the development dataset to the external datasets.

446

447

medRxiv preprint doi: https://doi.org/10.1101/2024.01.30.24301996; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

#### 448 **Discussion**

449 Given the impact of COVID-19 on society and healthcare, there is a need for simple and fast detection 450 of patients with a possible COVID-19 infection in the ED. The CoLab-score described in this study, is 451 a fast and accurate risk score to triage patients presenting at the ED based on routine blood 452 biomarkers. The prevalence-dependent binary CoLab-classification preserves a balance between PCR 453 testing - and not testing, even in situations of changing prevalence. In one third of the ED 454 presentations, PCR testing could be safely omitted with a negative predictive value of 0.995. At low or 455 rapidly decreasing prevalence, the CoLab-classification could save more than half of the PCR tests. 456 The main strength of this study is that the CoLab-score can be used as a means of early-warning or 457 triaging tool for the entire ED population, regardless of presenting symptoms. This is in contrast to the 458 vast majority of COVID-19 diagnostic models that have been developed on a sub-population of PCR-459 tested patients (Brinati et al., 2020; Fink et al., 2020; Giamello et al., 2020; Joshi et al., 2020; 460 Kurstjens et al., 2020; Plante et al., 2020; Qin et al., 2020; Tordjman et al., 2020). Moreover, the 461 CoLab-score requires only routine blood tests instead of (features from) imaging such as CT-scans or 462 one or more laboratory test results that are not routinely measured in the ED such as interleukin-6 or 3-463 hydroxybuteric acid (Wynants et al., 2020). Although this is a retrospective case-control study, there is 464 some unavoidable missing data. In our cohort 13 - 18% of the ED presentations could not be used due 465 to one or more missing laboratory results. This is similar to other studies; 22% (Kurstjens et al., 2020), 466 17% (Joshi et al., 2020) and 11% (Tordjman et al., 2020). We do not expect that presentations with 467 missing data lead to a severe inclusion bias, but important to note is that the full lab panel was not 468 always requested for pediatric, obstetric and surgery patients. Ideally, probabilities predicted by a 469 model should be well calibrated (Van Calster et al., 2019). However, when the prevalence changes 470 over time, the mean prevalence may not reflect the current prevalence of a center at any given time 471 and calibration is never guaranteed. We chose to categorize the linear predictor into discrete 472 prevalence-based scoring categories. A downside of the CoLab prevalence-dependent binary 473 classification is that false negative results may occur, this is mostly the case when the prevalence 474 increases rapidly. As the threshold depends on the prevalence of the previous week, the threshold is

medRxiv preprint doi: https://doi.org/10.1101/2024.01.30.24301996; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
 lagging behind the actual prevalence. Estimating the prevalence more frequently during rapidly

changing prevalence alleviates this problem but may be more time consuming and prone to stochastic
variation. Nevertheless, when absolute certainty to rule-out COVID-19 is required, a CoLab-score of 0
can still be used, unless the prevalence is greater than 40%. In this study we did not investigate
whether the CoLab-score might be increased by other virus infections, but in an historic patient cohort
we did not find discriminative ability in separating between influenza-PCR-negative and PCR-positive
patients (data not shown).

482 One study that was comparable to our study was published by Plante et. al. (Plante et al., 2020). Their

483 study is similar in terms of outcome and used pre-pandemic patients as controls and PCR positive

484 patients as cases. Also the input variables consisted solely of 15 routinely laboratory tests [4].

485 Interestingly, their machine learning approach also identified eosinophils, leukocytes, basophils,

486 erythrocytes, albumin and bilirubin as important features. However, one of the other contributing

487 features was bicarbonate, which is generally only requested for a subgroup of ED patients requiring

488 arterial blood gas analysis. This could explain the 63.6% drop outs due to missing data. Furthermore,

489 their model is not easily implemented in current hospital IT systems.

490 Currently, five hospitals in the Netherlands have already implemented the CoLab-score in daily patient

491 care in the ED, three other centers are in the process of implementation. Main reasons to adopt the

492 CoLab-score, were scarcity in PCR-reagents and long turnaround times of PCR results by centralized

493 PCR-facilities. This underlines the strengths of CoLab-score, i.e. it safely rules out COVID-19 for one

third of the ED patients and is instantly reported once the underlying laboratory results are available,

495 usually within one hour.

496 As we have developed a powerful tool to triage patients at the ED, future research is needed to

497 determine if the CoLab-score also identifies COVID-19 patients with new SARS-CoV-2 mutations.

498 However, since the CoLab-score reflects the biochemical consequences of the virus and not the virus

499 itself, we expect that the CoLab-score is also sensitive for future mutations of SARS-CoV-2.

medRxiv preprint doi: https://doi.org/10.1101/2024.01.30.24301996; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

## 500 **Funding**

501 This study was undertaken without any external funding.

## 502 Acknowledgements

503 Not applicable.

medRxiv preprint doi: https://doi.org/10.1101/2024.01.30.24301996; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

#### 504 **References**

| 5             | Δ | 5 |
|---------------|---|---|
| $\mathcal{I}$ | υ | 5 |

- 506 Albahri AS, Hamid RA, Alwan J k., Al-qays ZT, Zaidan AA, Zaidan BB, Albahri AOS, AlAmoodi AH,
- 507 Khlaf JM, Almahdi EM, Thabet E, Hadi SM, Mohammed KI, Alsalem MA, Al-Obaidi JR,
- 508 Madhloom HT. 2020. Role of biological Data Mining and Machine Learning Techniques in
- 509 Detecting and Diagnosing the Novel Coronavirus (COVID-19): A Systematic Review. *J Med Syst.*
- 510 doi:10.1007/s10916-020-01582-x
- 511 Brinati D, Campagner A, Ferrari D, Locatelli M, Banfi G, Cabitza F. 2020. Detection of COVID-19
- 512 Infection from Routine Blood Exams with Machine Learning: A Feasibility Study. J Med Syst
- 513 **44**:1–12. doi:10.1007/s10916-020-01597-4
- 514 Coronavirus Disease (COVID-19) Situation Reports. n.d.
- 515 https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/
- Efron B. 1983. Estimating the error rate of a prediction rule: Improvement on cross-validation. *J Am Stat Assoc* 78:316–331. doi:10.1080/01621459.1983.10477973
- 518 Fink DL, Khan PY, Goldman N, Cai J, Hone L, Mooney C, El-Shakankery KH, Sismey G, Whitford V,
- 519 Marks M, Thomas S. 2020. Development and internal validation of a diagnostic prediction model
- 520 for COVID-19 at time of admission to hospital. QJM An Int J Med. doi:10.1093/qjmed/hcaa305
- 521 Friedman J, Hastie T, Tibshirani R. 2010. Regularization paths for generalized linear models via
  522 coordinate descent. *J Stat Softw* 33:1–22. doi:10.18637/jss.v033.i01
- 523 Giamello JD, Paglietta G, Cavalot G, Allione A, Abram S, Dutto L, Bernardi S, Bernardi E, Tosello F,
- 524 Lauria G. 2020. A simple tool to help ruling-out Covid-19 in the emergency department: derivation
- 525 and validation of the LDH-CRP-Lymphocyte (LCL) score. *Emerg Care J* 16. 526 doi:10.4081/ecj.2020.9336
- 527 Harrell Jr FE. 2021. rms: Regression Modeling Strategies.
- Hooli S, King C. 2020. Generalizability of Coronavirus Disease 2019 (COVID-19) Clinical Prediction
   25

medRxiv preprint doi: https://doi.org/10.1101/2024.01.30.24301996; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
 Models. Clin Infect Dis 71:897-897. doi:10.1093/c1d/c1aa417

529

Joshi RP, Pejaver V, Hammarlund NE, Sung H, Lee SK, Furmanchuk A, Lee HY, Scott G, Gombar S,

- 531 Shah N, Shen S, Nassiri A, Schneider D, Ahmad FS, Liebovitz D, Kho A, Mooney S, Pinsky BA,
- 532 Banaei N. 2020. A predictive tool for identification of SARS-CoV-2 PCR-negative emergency
- 533 department patients using routine test results. J Clin Virol **129**:104502.
- 534 doi:10.1016/j.jcv.2020.104502
- 535 King G, Zeng L. 2001. Logistic Regression in Rare Events Data. *Polit Anal* 9:137–163.
  536 doi:10.1093/oxfordjournals.pan.a004868

537 Kurstjens S, van der Horst A, Herpers R, Geerits MWL, Kluiters-De Hingh YCM, Göttgens EL, Blaauw

538 MJT, Thelen MHM, Elisen MGLM, Kusters R. 2020. Rapid identification of SARS-CoV-2-

infected patients at the emergency department using routine testing. *Clin Chem Lab Med* **58**:1587–

540 1593. doi:10.1515/cclm-2020-0593

- 541 Lessmann N, Sánchez CI, Beenen L, Boulogne LH, Brink M, Calli E, Charbonnier JP, Dofferhoff T, 542 van Everdingen WM, Gerke PK, Geurts B, Gietema HA, Groeneveld M, van Harten L, Hendrix 543 N, Hendrix W, Huisman HJ, Išgum I, Jacobs C, Kluge R, Kok M, Krdzalic J, Lassen-Schmidt B, 544 van Leeuwen K, Meakin J, Overkamp M, van Rees Vellinga T, van Rikxoort EM, Samperna R, 545 Schaefer-Prokop C, Schalekamp S, Scholten ET, Sital C, Stöger JL, Teuwen J, Venkadesh KV, de 546 Vente C, Vermaat M, Xie W, de Wilde B, Prokop M, van Ginneken B. 2021. Automated 547 assessment of COVID-19 reporting and data system and chest CT severity scores in patients 548 suspected of having COVID-19 using artificial intelligence. Radiology 298:E18-E28. 549 doi:10.1148/RADIOL.2020202439
- 550 Linssen J, Ermens A, Berrevoets M, Seghezzi M, Previtali G, Brugge S van der S van der, Russcher H, 551 Verbon A, Gillis J, Riedl J, Jongh E de, Saker J, Münster M, Munnix ICA, Dofferhoff A, 552 Scharnhorst V, Ammerlaan H, Deiteren K, Bakker SJL, van Pelt LJ, Hingh YK De, Leers MPG, 553 van der Ven A. 2020. A novel haemocytometric covid-19 prognostic score developed and validated 554 in an observational multicentre european hospital-based study. Elife **9**:1–37.

medRxiv preprint doi: https://doi.org/10.1101/2024.01.30.24301996; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 555 doi:10.7554/eLife.63195

- 556 Plante TB, Blau AM, Berg AN, Weinberg AS, Jun IC, Tapson VF, Kanigan TS, Adib AB. 2020.
- 557 Development and external validation of a machine learning tool to rule out COVID-19 among
- adults in the emergency department using routine blood tests: A large, multicenter, real-world
- 559 study. J Med Internet Res 22:e24048. doi:10.2196/24048
- 560 Qin L, Yang Y, Cao Q, Cheng Z, Wang X, Sun Q, Yan F, Qu J, Yang W. 2020. A predictive model and
- scoring system combining clinical and CT characteristics for the diagnosis of COVID-19. *Eur Radiol* 30:6797–6807. doi:10.1007/s00330-020-07022-1
- 563 R Core Team. 2020. R: A Language and Environment for Statistical Computing.
- 564 Ricós C, Alvarez V, Cava F, García-Lario J V., Hernández A, Jiménez C V., Minchinela J, Perich C,
- Simón M. 1999. Current databases on biological variation: Pros, cons and progress. *Scand J Clin Lab Invest*. doi:10.1080/00365519950185229
- Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, Müller M. 2011. pROC: An opensource package for R and S+ to analyze and compare ROC curves. *BMC Bioinformatics* 12:77.
  doi:10.1186/1471-2105-12-77
- 570 Tibshirani R. 1996. Regression Shrinkage and Selection Via the Lasso. *J R Stat Soc Ser B* 58:267–288.
  571 doi:10.1111/j.2517-6161.1996.tb02080.x
- 572 Tordjman M, Mekki A, Mali RD, Saab I, Chassagnon G, Guillo E, Burns R, Eshagh D, Beaune S,
- 573 Madelin G, Bessis S, Feydy A, Mihoubi F, Doumenc B, Mouthon L, Carlier R-Y, Drapé J-L, Revel
- 574 M-P. 2020. Pre-test probability for SARS-Cov-2-related infection score: The PARIS score. *PLoS*575 *One* 15:e0243342. doi:10.1371/journal.pone.0243342
- 576 Van Calster B, McLernon DJ, Van Smeden M, Wynants L, Steyerberg EW, Bossuyt P, Collins GS,
- 577 MacAskill P, McLernon DJ, Moons KGM, Steyerberg EW, Van Calster B, Van Smeden M,
- 578 Vickers AJ. 2019. Calibration: The Achilles heel of predictive analytics. *BMC Med* 17:230.
- 579 doi:10.1186/s12916-019-1466-7

27

medRxiv preprint doi: https://doi.org/10.1101/2024.01.30.24301996; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 580 Wang F, Hou H, Wang T, Luo Y, Tang G, Wu S, Zhou H, Sun Z. 2020. Establishing a model for

- predicting the outcome of COVID-19 based on combination of laboratory tests. *Travel Med Infect Dis* 36:101782. doi:10.1016/j.tmaid.2020.101782
- 583 Wynants L, Van Calster B, Collins GS, Riley RD, Heinze G, Schuit E, Bonten MMJ, Damen JAA,
- 584 Debray TPA, De Vos M, Dhiman P, Haller MC, Harhay MO, Henckaerts L, Kreuzberger N,
- 585 Lohmann A, Luijken K, Ma J, Andaur Navarro CL, Reitsma JB, Sergeant JC, Shi C, Skoetz N,
- 586 Smits LJM, Snell KIE, Sperrin M, Spijker R, Steyerberg EW, Takada T, Van Kuijk SMJ, Van
- 587 Royen FS, Wallisch C, Hooft L, Moons KGM, Van Smeden M. 2020. Prediction models for
- 588 diagnosis and prognosis of covid-19: Systematic review and critical appraisal. BMJ 369:18.
- 589 doi:10.1136/bmj.m1328
- <sup>590</sup> Zeng Z, Ma Y, Zeng H, Huang P, Liu W, Jiang M, Xiang X, Deng D, Liao X, Chen P, Chen Y. 2021.
- Simple nomogram based on initial laboratory data for predicting the probability of ICU transfer of
  COVID-19 patients: Multicenter retrospective study. *J Med Virol* 93:434–440.
  doi:10.1002/jmv.26244
- Zhou Y, He Y, Yang H, Yu H, Wang T, Chen Z, Yao R, Liang Z. 2020. Development and validation a
  nomogram for predicting the risk of severe COVID-19: A multi-center study in Sichuan, China. *PLoS One* 15:e0233328. doi:10.1371/journal.pone.0233328
- 597 Zou H. 2006. The adaptive lasso and its oracle properties. J Am Stat Assoc 101:1418–1429.
  598 doi:10.1198/01621450600000735
- 599



Α









